Remove 2030 Remove Dosage Remove Vaccines
article thumbnail

3 of the year’s most notable FDA nods

PharmaVoice

Other PrEP regimens on the market require daily oral dosages or shots every few months, but the latest version is only administered twice a year. Now, the WHO’s aggressive goal to “ end HIV/AIDS ” by 2030 could be hampered by dramatic reductions in U.S. A long-time leader in vaccines, the U.K. While Enhertu pulled in about $3.8

FDA 130
article thumbnail

HPAPI contract manufacturing to value $14.6 billion by 2030

European Pharmaceutical Review

billion by 2030, according to a market report. However, during the second half, the surge in demand for vaccines to fight the coronavirus enhanced the industry’s need for raw materials and product intermediates of API molecules. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Dosage 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advanced Solutions for Sustained Delivery of Ocular Therapies

PharmTech

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Dosage 64
article thumbnail

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. Trends Pharmacol Sci. 2024;45(5):406-418.

article thumbnail

Driving drug innovation: developments in pharmaceutical capsules

European Pharmaceutical Review

The second most commonly used pharmaceutical dosage form, capsules, are anticipated to be a $5.2 billion market by 2030, growing from a 2020 value of around $2.4 Compared with other oral solid dosage forms (OSDs), capsules also offer the easiest method to achieve fixed-dose combinations (FDCs) of incompatible drug substances.

Dosage 124
article thumbnail

ten23 health Joins Gerresheimer, SCHOTT, Stevanato Group in ‘Alliance for RTU’

PharmTech

Recent Videos Related Content Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report Susan Haigney June 30th 2025 Article The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

Dosage 45
article thumbnail

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

PharmTech

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com Hikma Pharmaceuticals USA announced on June 28, 2025 that it is investing $1 billion by 2030 to expand its generic-drug R&D and manufacturing capabilities in its Ohio and New Jersey, United States, facilities.

Dosage 59